T A Paine1, A O'Hara, B Plaut, D C Lowes. 1. Department of Neuroscience, Oberlin College, Science Center A241, 119 Woodland St., Oberlin, OH, 44074, USA, tpaine@oberlin.edu.
Abstract
RATIONALE: Decision-making is a complex cognitive process that is mediated, in part, by subregions of the medial prefrontal cortex (PFC). Decision-making is impaired in a number of psychiatric conditions including schizophrenia. Notably, people with schizophrenia exhibit reductions in GABA function in the same PFC areas that are implicated in decision-making. For example, expression of the GABA-synthesizing enzyme GAD67 is reduced in the dorsolateral PFC of people with schizophrenia. OBJECTIVES: The goal of this experiment was to determine whether disrupting cortical GABA transmission impairs decision-making using a rodent gambling task (rGT). METHODS: Rats were trained on the rGT until they reached stable performance and then were implanted with guide cannulae aimed at the medial PFC. Following recovery, the effects of intra-PFC infusions of the GABAA receptor antagonist bicuculline methiodide (BMI) or the GABA synthesis inhibitor L-allylglycine (LAG) on performance on the rGT were assessed. RESULTS: Intracortical infusions of BMI (25 ng/μl/side), but not LAG (10 μg/μl/side), altered decision-making. Following BMI infusions, rats made fewer advantageous choices. Follow-up experiments suggested that the change in decision-making was due to a change in the sensitivity to the punishments, rather than a change in the sensitivity to reward magnitudes, associated with each outcome. LAG infusions increased premature responding, a measure of response inhibition, but did not affect decision-making. CONCLUSIONS: Blocking GABAA receptors, but not inhibiting cortical GABA synthesis, within the medial PFC affects decision-making in the rGT. These data provide proof-of-concept evidence that disruptions in GABA transmission can contribute to the decision-making deficits in schizophrenia.
RATIONALE: Decision-making is a complex cognitive process that is mediated, in part, by subregions of the medial prefrontal cortex (PFC). Decision-making is impaired in a number of psychiatric conditions including schizophrenia. Notably, people with schizophrenia exhibit reductions in GABA function in the same PFC areas that are implicated in decision-making. For example, expression of the GABA-synthesizing enzyme GAD67 is reduced in the dorsolateral PFC of people with schizophrenia. OBJECTIVES: The goal of this experiment was to determine whether disrupting cortical GABA transmission impairs decision-making using a rodent gambling task (rGT). METHODS:Rats were trained on the rGT until they reached stable performance and then were implanted with guide cannulae aimed at the medial PFC. Following recovery, the effects of intra-PFC infusions of the GABAA receptor antagonist bicuculline methiodide (BMI) or the GABA synthesis inhibitor L-allylglycine (LAG) on performance on the rGT were assessed. RESULTS: Intracortical infusions of BMI (25 ng/μl/side), but not LAG (10 μg/μl/side), altered decision-making. Following BMI infusions, rats made fewer advantageous choices. Follow-up experiments suggested that the change in decision-making was due to a change in the sensitivity to the punishments, rather than a change in the sensitivity to reward magnitudes, associated with each outcome. LAG infusions increased premature responding, a measure of response inhibition, but did not affect decision-making. CONCLUSIONS: Blocking GABAA receptors, but not inhibiting cortical GABA synthesis, within the medial PFC affects decision-making in the rGT. These data provide proof-of-concept evidence that disruptions in GABA transmission can contribute to the decision-making deficits in schizophrenia.
Authors: Alexander M Kleschevnikov; Pavel V Belichenko; Mehrdad Faizi; Lucia F Jacobs; Khin Htun; Mehrdad Shamloo; William C Mobley Journal: J Neurosci Date: 2012-07-04 Impact factor: 6.167
Authors: Richard J Beninger; James Wasserman; Katherine Zanibbi; Danielle Charbonneau; Jennifer Mangels; Bruce V Beninger Journal: Schizophr Res Date: 2003-06-01 Impact factor: 4.939
Authors: Fiona D Zeeb; P J J Baarendse; L J M J Vanderschuren; Catharine A Winstanley Journal: Psychopharmacology (Berl) Date: 2015-09-21 Impact factor: 4.530
Authors: Caitlin A Orsini; Sara C Heshmati; Tyler S Garman; Shannon C Wall; Jennifer L Bizon; Barry Setlow Journal: Neuropharmacology Date: 2018-07-20 Impact factor: 5.250